

Contact RIGEL ONECARE
Phone: 833-744-3562 Fax: 833-397-4435
Email: support@RigelONECARE.com
Available: M – F, 8am – 8pm ET

INDICATION

VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative, estrogen receptor 1 (*ESR1*)–mutated advanced or metastatic breast cancer, as detected by an FDA–authorized test, with disease progression following at least one line of endocrine therapy.

Please see Important Safety Information, including Warnings about QTc Interval Prolongation and Embryo-Fetal Toxicity on page 3.

The ICD-10-CM diagnosis codes listed below are provided only as examples of potentially relevant codes.
The information provided in this guide should in no way be considered a guarantee of coverage or reimbursement for any product or service.

NATIONAL DRUG CODES (NDC) ¹			
Administration method	Dose	11-Digit NDC	Description
Oral	100 mg	71332-0007-30	Bottle of 30 tablets
Oral	200 mg	71332-0008-30	Bottle of 30 tablets
DIAGNOSIS CODES ²			
ICD-10-CM code	Description		
	Malignant neoplasm of breast		
C50.011	Malignant neoplasm of nipple and areola, right female breast		
C50.012	Malignant neoplasm of nipple and areola, left female breast		
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast		
C50.021	Malignant neoplasm of nipple and areola, right male breast		
C50.022	Malignant neoplasm of nipple and areola, left male breast		
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast		
C50.111	Malignant neoplasm of central portion of right female breast		
C50.112	Malignant neoplasm of central portion of left female breast		
C50.119	Malignant neoplasm of central portion of unspecified female breast		
C50.121	Malignant neoplasm of central portion of right male breast		
C50.122	Malignant neoplasm of central portion of left male breast		
C50.129	Malignant neoplasm of central portion of unspecified male breast		
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast		
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast		
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast		
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast		
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast		
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast		
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast		
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast		
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast		
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast		
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast		
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast		
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast		
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast		
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast		
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast		
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast		
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast		
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast		

ICD-10-CM code	Description
	Malignant neoplasm of breast (cont.)
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast
C50.611	Malignant neoplasm of axillary tail of right female breast
C50.612	Malignant neoplasm of axillary tail of left female breast
C50.619	Malignant neoplasm of axillary tail of unspecified female breast
C50.621	Malignant neoplasm of axillary tail of right male breast
C50.622	Malignant neoplasm of axillary tail of left male breast
C50.629	Malignant neoplasm of axillary tail of unspecified male breast
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast
C50.821	Malignant neoplasm of overlapping sites of right male breast
C50.822	Malignant neoplasm of overlapping sites of left male breast
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.912	Malignant neoplasm of unspecified site of left female breast
C50.919	Malignant neoplasm of unspecified site of unspecified female breast
C50.921	Malignant neoplasm of unspecified site of right male breast
C50.922	Malignant neoplasm of unspecified site of left male breast
C50.929	Malignant neoplasm of unspecified site of unspecified male breast
Z85.3	Personal history of malignant neoplasm of breast
	Metastasis to bone and bone marrow
C79.51	Secondary malignant neoplasm of bone
C79.52	Secondary malignant neoplasm of bone marrow
	Metastasis to lung and pleura
C78.00	Secondary malignant neoplasm of unspecified lung
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
C78.1	Secondary malignant neoplasm of mediastinum
C78.2	Secondary malignant neoplasm of pleura
C78.30	Secondary malignant neoplasm of unspecified respiratory organ
C78.39	Secondary malignant neoplasm of other respiratory organs
	Metastasis to lymph nodes
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified

ICD-10-CM code	Description
	Metastasis to liver
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
	Metastasis to brain
C79.32	Secondary malignant neoplasm of cerebral meninges

References: 1. VEPPANU [prescribing information]. South San Francisco, CA: Rigel Pharmaceuticals, Inc.; 2026.
2. Centers for Medicare & Medicaid Services. 2026 ICD-10-CM files.
Accessed April 1, 2026. <https://www.cms.gov/files/zip/april-1-2026-code-descriptions-tabular-order.zip>

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

QTc Interval Prolongation

VEPPANU can cause QT (QTc) interval prolongation. Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to and during treatment with VEPPANU. Perform an ECG prior to initiation of treatment with VEPPANU and do not initiate VEPPANU in patients with QTc >470 msec. Repeat ECG approximately 4 weeks after initiating treatment and as clinically indicated. Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval.

Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, VEPPANU can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with VEPPANU and for 2 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with VEPPANU and for 2 weeks after the last dose.

ADVERSE REACTIONS

Serious adverse reactions occurred in 9% of patients who received VEPPANU. The serious adverse reactions included any fracture (1.3%), fall, hypercalcemia, hepatic injury, pneumonia, musculoskeletal pain (0.6% each), and QTc prolonged (0.3%). Fatal adverse reactions occurred in 1.0% of patients who received VEPPANU, including dyspnea, cerebral ischemia, and unknown cause (one patient each).

Permanent discontinuation of VEPPANU due to an adverse reaction occurred in 2.9% of patients, dosage interruptions of VEPPANU due to an adverse reaction occurred in 14% of patients, and dosage reductions of VEPPANU due to an adverse reaction occurred in 1.9% of patients.

The most common ($\geq 10\%$) adverse reactions, including laboratory abnormalities, were decreased white blood cells, increased AST, musculoskeletal pain, fatigue, decreased hemoglobin, decreased neutrophils, increased ALT, increased alkaline phosphatase, nausea, decreased blood potassium, increased bilirubin, decreased appetite, electrocardiogram QT prolonged, decreased platelets, and constipation.

Clinically relevant adverse reactions in <10% of patients who received VEPPANU included headache, hot flush, diarrhea, vomiting, bradycardia, and urinary tract infection.

DRUG INTERACTIONS

- **Strong CYP3A Inhibitors:** Avoid concomitant use of VEPPANU with strong CYP3A inhibitors. If concomitant use cannot be avoided, reduce VEPPANU dosage.
- **Strong CYP3A Inducers:** Avoid concomitant use with strong CYP3A inducers in patients receiving VEPPANU. If concomitant use cannot be avoided, increase VEPPANU dosage.
- **Certain P-gp Substrates:** Avoid concomitant use with certain P-gp substrates where minimal increases in concentration may lead to serious adverse reactions.
- **Certain UGT1A9 Substrates:** Refer to the Prescribing Information for UGT1A9 substrates where minimal increases in the concentration may lead to serious adverse reactions.

Avoid concomitant use of VEPPANU with other drugs with a known potential to prolong the QTc interval.

LACTATION

Advise lactating women not to breastfeed during treatment with VEPPANU and for 2 weeks after the last dose.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Important Safety Information and Full Prescribing Information at VEPPANUhcp.com.